Axovant Sciences Ltd (NASDAQ:AXON) Director George Bickerstaff acquired 25,000 shares of the firm’s stock in a transaction dated Tuesday, February 27th. The shares were purchased at an average price of $1.50 per share, with a total value of $37,500.00. The purchase was disclosed in a filing with the SEC, which is accessible through this link.
Shares of Axovant Sciences Ltd (NASDAQ AXON) traded up $0.05 during trading on Friday, reaching $1.51. The company had a trading volume of 729,273 shares, compared to its average volume of 791,060. Axovant Sciences Ltd has a 1-year low of $1.40 and a 1-year high of $27.98. The company has a market capitalization of $162.76, a P/E ratio of -0.66 and a beta of -0.46. The company has a debt-to-equity ratio of 0.45, a current ratio of 4.58 and a quick ratio of 4.58.
A number of institutional investors have recently made changes to their positions in the stock. BlackRock Inc. grew its holdings in Axovant Sciences by 99.8% during the fourth quarter. BlackRock Inc. now owns 2,912,219 shares of the biotechnology company’s stock worth $15,347,000 after buying an additional 1,454,454 shares in the last quarter. OxFORD Asset Management LLP grew its holdings in Axovant Sciences by 842.1% during the third quarter. OxFORD Asset Management LLP now owns 869,834 shares of the biotechnology company’s stock worth $5,838,000 after buying an additional 777,505 shares in the last quarter. Eagle Asset Management Inc. bought a new stake in Axovant Sciences during the third quarter worth $4,471,000. Deutsche Bank AG grew its holdings in Axovant Sciences by 7.0% during the fourth quarter. Deutsche Bank AG now owns 548,728 shares of the biotechnology company’s stock worth $2,891,000 after buying an additional 35,878 shares in the last quarter. Finally, State Street Corp grew its holdings in Axovant Sciences by 52.8% during the second quarter. State Street Corp now owns 546,920 shares of the biotechnology company’s stock worth $12,682,000 after buying an additional 188,945 shares in the last quarter. Institutional investors and hedge funds own 93.12% of the company’s stock.
Several research firms have recently commented on AXON. ValuEngine upgraded Axovant Sciences from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. Zacks Investment Research upgraded Axovant Sciences from a “hold” rating to a “buy” rating and set a $2.25 price objective for the company in a report on Wednesday, January 31st. Cowen restated a “hold” rating on shares of Axovant Sciences in a report on Tuesday, February 13th. HC Wainwright restated a “buy” rating and set a $11.00 price objective on shares of Axovant Sciences in a report on Friday, December 1st. Finally, BidaskClub upgraded Axovant Sciences from a “sell” rating to a “hold” rating in a report on Wednesday, November 22nd. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $13.61.
ILLEGAL ACTIVITY NOTICE: This story was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/03/18/insider-buying-axovant-sciences-ltd-axon-director-purchases-25000-shares-of-stock.html.
Axovant Sciences Company Profile
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.